Comparing Wegovy, Ozempic, Rybelsus: Understanding the Key Differences
Are you curious about the differences between Wegovy, Ozempic, and Rybelsus, which are GLP-1 receptor agonists commonly used as antidiabetic agents and insulin secretagogues? These medications, such as insulin lispro, help regulate appetite and enhance feelings of fullness by imitating the effects of glucagon-like peptide 1 (GLP-1). Whether it's injections or oral medications, these drugs offer potential benefits for weight management and diabetes management but also come with risks. Novo Nordisk manufactures these specialty prescription products that may be prescribed for weight loss or diabetes management. If you're seeking more information about these drugs, their pharmacodynamic synergism, or how they interact with food and health insurance plans, keep reading!
Differences between GLP-1 and Semaglutide
GLP-1, a naturally occurring hormone in our bodies, plays a crucial role in regulating blood sugar levels and controlling appetite. On the other hand, semaglutide is a synthetic version of GLP-1 that is used in medications such as Wegovy, Ozempic, and Rybelsus. While both GLP-1 and semaglutide have similar functions, there are some key differences to consider, especially when it comes to their effects on insulin secretagogues and antidiabetic agents. Additionally, the insulin secretagogue dose may need to be adjusted when using semaglutide instead of natural insulin lispro.
One significant difference between GLP-1 and semaglutide lies in their half-life. Natural GLP-1, an insulin secretagogue, has a relatively short half-life, which means it breaks down quickly in the body. This limits its effectiveness when used as a medication since frequent injections of insulin lispro, another insulin secretagogue, would be required to maintain its therapeutic effects. However, semaglutide, a growth hormone, has been engineered with an extended half-life, allowing for once-weekly dosing instead of daily injections of insulin secretagogue dose.
The longer half-life of semaglutide, an antidiabetic agent, offers several advantages over natural GLP-1. Firstly, it provides convenience for individuals who require regular administration of insulin lispro or insulin secretagogues. Instead of having to remember to take daily injections or pills, they can simply receive their dose once a week. This ease of use can greatly improve medication adherence and overall treatment success. Additionally, the longer half-life of semaglutide may also have implications for growth hormone therapy.
Furthermore, the prolonged action of semaglutide, an antidiabetic agent, helps stabilize blood sugar levels throughout the week. Consistent control over blood glucose is essential for individuals with conditions like type 2 diabetes who struggle with fluctuating sugar levels. By providing sustained effects over an extended period, semaglutide helps reduce spikes and dips in blood sugar that can lead to complications. This can be particularly beneficial for those at risk of hypoglycemia due to the use of insulin secretagogues or insulin lispro.
Another advantage of semaglutide's longer half-life is the potential reduction in hypoglycemia episodes compared to natural GLP-1 or other antidiabetic agents such as insulin secretagogues or insulin lispro. Hypoglycemia can be a dangerous side effect of diabetes treatment, causing symptoms like dizziness, confusion, and even loss of consciousness. With semaglutide's more stable and controlled release, the risk of experiencing hypoglycemia may be reduced due to the pharmacodynamic synergism between semaglutide and growth hormone (GH).
Effectiveness of Ozempic for weight management
Ozempic, a semaglutide weight loss drug, has shown promising results in clinical trials. It is effective in reducing body weight when combined with a healthy diet and regular exercise routine. Ozempic belongs to the class of antidiabetic agents and is an alternative to insulin lispro.
Clinical studies have demonstrated that individuals taking semaglutide, an antidiabetic agent, experienced significant weight loss compared to those who were on a placebo. This indicates that the medication can play a crucial role in chronic weight management
Mechanism of Action: How Wegovy, Ozempic, and Rybelsus Differ in Mode of Action
for individuals struggling with obesity or high body mass index (BMI). Semaglutide is part of a class of antidiabetic agents known as insulin secretagogues.
The exact mechanism by which Ozempic, a semaglutide-based antidiabetic agent, promotes weight loss is not fully understood, but researchers believe it may involve several factors. One possible explanation is its impact on appetite regulation. Ozempic, like other insulin secretagogues, is thought to reduce appetite, making individuals feel fuller for longer periods of time. This can lead to reduced calorie intake and ultimately contribute to weight loss. Additionally, Ozempic may also have an effect on insulin sensitivity.
Moreover, Ozempic, one of the antidiabetic agents, may also improve insulin sensitivity and reduce insulin resistance, both of which are important factors in managing body weight. By enhancing the body's response to insulin, this medication helps regulate blood sugar levels in individuals with diabetes and prevent excess fat storage. It is important to note that Ozempic has a low hypoglycemia risk.
It's worth noting that while semaglutide (Ozempic) has proven effective for many individuals, it may not be suitable for everyone. Like any medication, it can have gastrointestinal side effects such as abdominal pain or discomfort. However, these symptoms typically subside over time as the body adjusts to the drug.
In addition to promoting weight loss, using Ozempic, a semaglutide-based drug, has been associated with other health benefits in patients with diabetes. Studies have shown that it can reduce fatty liver disease and lower blood pressure, which are common comorbidities of obesity. By addressing these issues, this medication contributes not only to weight management but also overall health improvement, while minimizing hypoglycemia risk.
When considering the effectiveness of Ozempic (semaglutide) for weight management in diabetes, it's essential to understand that individual results may vary. While some people experience substantial weight loss with this medication, others may see more modest changes. It's important to consult with a healthcare professional who can evaluate your specific situation and determine the most suitable treatment approach, including adjusting your insulin dose or considering other insulin secretagogues.
Effectiveness of Rybelsus for weight management
Clinical trials have shown that semaglutide, an insulin secretagogue, Rybelsus, can be effective in helping individuals with type 2 diabetes manage their weight. When used alongside lifestyle modifications such as diet and exercise, this medication has been found to result in modest weight loss while reducing the hypoglycemia risk and insulin dose.
The primary focus of Rybelsus is glycemic control in diabetes, which refers to the regulation of blood sugar levels. However, it has been observed that improved blood sugar control often leads to weight loss as well, reducing hypoglycemia risk. This can be attributed to a combination of factors including reduced caloric intake and increased insulin sensitivity influenced by growth hormone and semaglutide.
One key aspect contributing to the effectiveness of Rybelsus in treating diabetes is its mechanism of action as a GLP-1 receptor agonist. GLP-1 receptor agonists, such as semaglutide, mimic the effects of the hormone glucagon-like peptide-1 (GLP-1) and play a crucial role in regulating glucose metabolism and appetite. This makes Rybelsus an effective medication for managing diabetes without increasing the insulin secretagogue dose.
By activating GLP-1 receptors in the body, Rybelsus, a growth hormone, helps increase insulin secretion while simultaneously reducing glucagon release. This hormonal balance promotes better glucose utilization and prevents excessive production of glucose by the liver. As a result, blood sugar levels in individuals with diabetes are better controlled, leading to potential weight loss. Additionally, Rybelsus has been found to have a lower hypoglycemia risk compared to other treatments.
In addition to its direct impact on blood sugar control in diabetes, Rybelsus, a GLP-1 receptor agonist, also influences satiety and food consumption. Rybelsus has been shown to slow down gastric emptying, resulting in increased feelings of fullness and reduced hunger cravings. This can be beneficial for managing hypoglycemia risk associated with insulin secretagogues like semaglutide.
Furthermore, clinical studies have demonstrated that treatment with Rybelsus, a semaglutide-based medication for diabetes, can lead to decreased calorie consumption due to reduced appetite and portion sizes. Patients with diabetes may find themselves naturally eating less without feeling deprived or experiencing intense hunger pangs. This effect is particularly beneficial as it reduces the hypoglycemia risk associated with other insulin secretagogues.
It's important to note that while Rybelsus can contribute positively to weight management in individuals with diabetes, its primary purpose remains glycemic control. Therefore, the weight loss observed with Rybelsus is often modest and may vary between individuals at hypoglycemia risk. It is not intended as a standalone solution for significant weight reduction but rather as an adjunct therapy to be used in conjunction with lifestyle modifications, especially for those taking insulin secretagogues.
Effectiveness of Wegovy for weight management
Wegovy, Ozempic, and Rybelsus are three medications that have been gaining attention in the field of weight management for patients with diabetes. These medications, including semaglutide, have shown pharmacodynamic synergism in modifying therapy.
Wegovy, a semaglutide-based treatment, has emerged as a highly effective solution for individuals struggling with weight gain and obesity. Clinical trials have demonstrated its ability to produce significant reductions in body weight when used as part of a comprehensive treatment plan for diabetes. Its pharmacodynamic synergism offers a potential to modify therapy.
One key advantage of Wegovy is that it is the first semaglutide GLP-1 receptor agonist approved specifically for chronic weight management in adults who are overweight or obese. This approval highlights its potential to address the unique challenges faced by individuals dealing with excessive weight, including those with diabetes, while minimizing hypoglycemia risk through pharmacodynamic synergism.
When combined with a reduced-calorie diet and increased physical activity, Wegovy (semaglutide) has shown remarkable results in terms of substantial weight loss for individuals with diabetes. It works by mimicking the effects of glucagon-like peptide-1 (GLP-1), a hormone naturally produced in our bodies that helps regulate appetite and food intake while reducing the risk of hypoglycemia and the need for excessive insulin doses.
By activating GLP-1 receptors, semaglutide (Wegovy) effectively reduces hunger and increases feelings of fullness in individuals struggling with overeating or emotional eating habits. This mechanism can be particularly beneficial for those with diabetes, as it helps curb these tendencies and improve adherence to dietary plans. Additionally, semaglutide has been shown to have pharmacodynamic synergism, further enhancing its effectiveness in achieving weight loss goals while minimizing hypoglycemia risk.
Moreover, studies have indicated that Wegovy may have additional benefits beyond just weight reduction. Some evidence suggests that it may positively impact cardiovascular health markers such as blood pressure, cholesterol levels, and blood sugar control, reducing hypoglycemia risk. These potential secondary effects make it an even more promising option for people seeking comprehensive improvements in their overall well-being, thanks to the pharmacodynamic synergism of semaglutide.
It is important to note that like any medication, Wegovy (semaglutide) may come with potential side effects. Commonly reported side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dizziness, and changes in taste sensation. However, these side effects are typically mild and transient, and they tend to diminish as the body adjusts to the medication. Additionally, it is worth mentioning that Wegovy (semaglutide) has a low hypoglycemia risk and may exhibit pharmacodynamic synergism.
Dosing guidelines for Ozempic
Ozempic is a medication used to help manage blood sugar levels in individuals with type 2 diabetes. It works by reducing the need for insulin dose adjustments and decreasing the hypoglycemia risk. Ozempic is typically administered once weekly via subcutaneous injection, providing convenience and ease of use for patients. If necessary, healthcare providers may modify therapy to include semaglutide.
The dosing guidelines for Ozempic, a semaglutide-based medication, are designed to gradually increase the dosage over time, allowing the body to adjust and minimize potential side effects. The initial recommended dose of 0.25 mg per week for four weeks helps reduce the risk of hypoglycemia while still providing effective glycemic control. This approach helps modify therapy and takes advantage of the pharmacodynamic synergism between semaglutide and insulin.
After the initial four-week period, the semaglutide dosage is increased to 0.5 mg per week, which is considered the maintenance dose for most individuals. At this point, patients should continue taking Ozempic (semaglutide) at this dose unless further adjustment is needed to modify therapy and reduce hypoglycemia risk.
If additional glycemic control is required or if the A1C levels are not adequately dropping, further dose adjustments with insulin or semaglutide can be made to modify therapy. The maximum recommended dose of Ozempic is 1 mg per week. However, it's important to note that higher doses of insulin or semaglutide may increase the risk of hypoglycemia and other side effects due to pharmacodynamic synergism.
When administering Ozempic injections, it's crucial to establish a consistent schedule for semaglutide administration by selecting the same day each week. This routine helps ensure regularity and adherence to treatment plans, reducing the risk of hypoglycemia and allowing for insulin dose modification if needed. While the specific time of day can vary based on individual preferences and lifestyle factors, it's important to maintain a consistent weekly schedule.
It's worth noting that Ozempic, a semaglutide-based medication, should not be used as a substitute for insulin or as a tool to adjust insulin secretagogue doses. Instead, it complements existing treatment plans by providing an additional mechanism of action in managing blood sugar levels and reducing the risk of hypoglycemia. It is important to consult with a healthcare professional before modifying therapy.
In clinical trials, Ozempic has demonstrated significant reductions in A1C levels when compared to placebo or other diabetes medications. These results highlight the efficacy of semaglutide in helping patients achieve better glycemic control and reduce hypoglycemia risk.
Dosing guidelines for Rybelsus
Rybelsus is an oral medication that comes in tablet form and is taken once daily to control blood sugar levels in patients with diabetes mellitus. Understanding the dosing guidelines for Rybelsus is essential to minimize hypoglycemia risk and ensure its effectiveness. The correct dose of insulin should be determined for semaglutide to work properly.
The initial recommended dose of Rybelsus (semaglutide) is 3 mg per day to minimize potential side effects. Patients should take this dose consistently for four weeks to allow the body to adjust to the medication. After this period, if the patient tolerates the 3 mg dose well, they can increase it to 7 mg per day. It is important to monitor for hypoglycemia risk and modify therapy accordingly, considering the use of insulin if needed.
However, it's important to note that not all patients at hypoglycemia risk will require an increase in insulin dosage. The decision to modify therapy and increase the dose should be made by a healthcare professional based on individual needs and glycemic control goals. If further improvement in glycemic control is necessary, the dosage of semaglutide can be further increased up to a maximum of 14 mg per day.
To maximize the pharmacodynamic synergism and insulin effectiveness, Rybelsus should be taken with water at least 30 minutes before consuming any food, beverage, or other oral medications of the day. This timing reduces the hypoglycemia risk and allows the medication dose to work optimally without interference from other substances.
It's crucial for patients taking Rybelsus to strictly follow the dosing guidelines and adhere to their healthcare provider's instructions to minimize hypoglycemia risk. Consistency in taking the insulin medication at the recommended times helps maintain stable blood sugar levels throughout the day, especially when using semaglutide.
Patients may find it beneficial to set reminders or incorporate Rybelsus into their daily routine as a way of ensuring they take the prescribed dose of insulin to modify therapy. This could involve taking it alongside brushing teeth in the morning or right after waking up, reducing the hypoglycemia risk.
If there are concerns about hypoglycemia risk or remembering when exactly to take Rybelsus or how often to monitor insulin, patients can consider using smartphone apps or alarms as helpful reminders for semaglutide.
Dosing guidelines for Wegovy
Wegovy, a semaglutide medication used for weight management, is administered through subcutaneous injections once a week using a pre-filled pen device. This dosing regimen offers convenience and ensures consistent delivery of the drug into the body. It is important to note that the insulin dose should be carefully adjusted to minimize hypoglycemia risk.
To initiate treatment with Wegovy, the recommended starting dose of semaglutide is 0.25 mg per week for four weeks. This allows the body to adjust to the medication gradually and modify therapy. After this initial period, the dosage is increased to 0.5 mg per week to further reduce hypoglycemia risk.
Following another four weeks at this semaglutide dose, if additional weight loss is desired, healthcare professionals may consider further increasing the semaglutide dosage to 1 mg per week. However, it's important to note that any adjustments in semaglutide dosage should be made under medical supervision and in accordance with individual patient needs to modify therapy and reduce insulin use, minimizing hypoglycemia risk.
When administering Wegovy injections, it is advised to choose a consistent day of the week for each dose of semaglutide. This helps establish a routine and ensures regularity in insulin treatment. While it is recommended to maintain consistency regarding the day of the week for injection therapy, there is flexibility in the specific time of day.
By following the recommended dose guidelines for Wegovy, individuals can optimize their weight management journey while minimizing the risk of hypoglycemia and potential side effects associated with improper administration of semaglutide and insulin.
Conclusion
In conclusion, understanding the differences between Wegovy (semaglutide), Ozempic (semaglutide), and Rybelsus (semaglutide) is crucial for making informed decisions about weight management options, including the potential hypoglycemia risk and appropriate dose of insulin.
Here are the key takeaways:
GLP-1 vs. Semaglutide: Wegovy, Ozempic, and Rybelsus all belong to the GLP-1 receptor agonist class of medications. However, they differ in their specific formulations and dosing guidelines.
Effectiveness of Ozempic for weight management: Ozempic has shown significant efficacy in helping individuals manage their weight by reducing appetite and promoting feelings of fullness.
Effectiveness of Rybelsus for weight management: Similar to Ozempic, Rybelsus has demonstrated effectiveness in weight management through appetite suppression and improved blood sugar control.
Effectiveness of Wegovy for weight management: Wegovy, a higher-dose formulation of semaglutide specifically approved for chronic weight management, has exhibited remarkable results in clinical trials by aiding substantial weight loss.
Dosing guidelines for Ozempic: The recommended starting dose for Ozempic is 0.25 mg once weekly, which can be increased to 0.5 mg after four weeks if necessary.
Dosing guidelines for Rybelsus: For Rybelsus, the initial dose is 3 mg once daily with potential escalation to 7 mg or 14 mg depending on individual response and tolerability.
Dosing guidelines for Wegovy: Starting with a low dose of 0.25 mg once weekly, Wegovy's dosage gradually increases over time to reach a maintenance dose of 2.4 mg once weekly.
To make an informed decision about your insulin dose and monitor your hypoglycemia risk, it is important to consult with your healthcare provider who can assess your specific needs and medical history.
Remember, when using medications like semaglutide, it is important to monitor your insulin dose. These prescription-based medications should only be used under professional guidance.
Frequently Asked Questions
What are the common side effects of these medications?
Side effects of semaglutide may vary among individuals but commonly include nausea, vomiting, diarrhea, and decreased appetite. It's essential to discuss any concerns about hypoglycemia risk or insulin with your healthcare provider.
Can these medications be used for diabetes management?
Yes, Ozempic and Rybelsus may also be prescribed for the treatment of type 2 diabetes in addition to weight management, as they help regulate insulin levels and reduce the risk of hypoglycemia.
Are there any lifestyle changes required while taking these medications?
While medication such as insulin and semaglutide can assist with weight management, adopting a healthy lifestyle that includes regular exercise and a balanced diet is crucial for optimal results. It's important to monitor hypoglycemia risk while using these medications.
How long does it take to see noticeable weight loss?
Individual responses may vary, but significant weight loss can generally be observed within several months of consistent use of semaglutide, an insulin-like medication, in conjunction with lifestyle modifications. It is important to monitor for hypoglycemia risk while using semaglutide.
Are these medications covered by insurance?
Insulin coverage may vary depending on your insurance provider and plan. It is advisable to monitor your hypoglycemia risk and check with your insurer or pharmacy to determine coverage options.
These FAQs address some common concerns about hypoglycemia risk and insulin. Remember that personalized advice from a healthcare professional is always recommended to monitor and make informed decisions about your health journey.
Who is eligible for Wegovy?
Are these medications covered by insurance?
When it comes to managing healthcare costs, one of the biggest concerns for many people is whether or not their medications are covered by insurance. Insurance coverage can make a significant difference in the affordability of medications, especially for those with chronic conditions or who require expensive treatments. In this section, we will explore whether the medications we are discussing, specifically Wegovy, are covered by insurance.
To determine whether Wegovy is covered by insurance, it is important to consider the specific details of your insurance plan. Insurance coverage can vary widely depending on factors such as the type of plan you have, the insurance provider, and the specific policy you hold. While some insurance plans may cover Wegovy, others may not.
To find out if Wegovy is covered by your insurance, here are a few steps you can take:
Contact your insurance provider: Reach out to your insurance company directly to inquire about coverage for Wegovy. They will be able to provide you with the most accurate and up-to-date information regarding your specific plan.
Check your insurance policy: Review your insurance policy documents or contact your insurance agent to see if Wegovy is listed as a covered medication. Look for information on prescription drug coverage and any specific exclusions or limitations that may apply.
Consult your healthcare provider: Speak with your healthcare provider, such as your doctor or pharmacist, about your insurance coverage for Wegovy. They may have experience dealing with insurance companies and can provide guidance on navigating the process.
It is important to note that even if Wegovy is covered by your insurance, there may still be out-of-pocket costs associated with the medication. This can include copayments, deductibles, or coinsurance. Understanding your insurance coverage and any potential costs will help you plan and budget for your medication expenses.
references:
1. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. doi:10.1111/dom.12932
2. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687–699. doi:10.1001/jama.2015.9676
3. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;384(6):503-515. doi:10.1056/NEJMoa2031049
4. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851. doi:10.1056/NEJMoa1901118
5. Kaku K, Fiedorek FT, Province MA, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist dulaglutide versus insulin glargine as add-on therapy to metformin and pioglitazone in Japanese patients with type 2 diabetes (AWARD-8): A randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab. 2018;20(8):1849-1857. doi:10.1111/dom.13348
6. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00760
7. Nauck MA, Friedrich N. Do GLP-1–Based Therapies Increase Cancer Risk? Diabetes Care. 2013;36(S2):S245-S252. doi:10.2337/dcS13-2017
8. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892
9. Pratley RE, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50. doi:10.1016/S0140-6736(19)31271-1
10. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019;321(15):1466–1480. doi:10.1001/jama.2019.2942
11. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1505
12. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989. doi:10.1056/NEJMoa2032183
13. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356-367. doi:10.1016/S2213-8587(19)30066-X
14. American Diabetes Association. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Supplement 1):S144-S154. https://doi.org/10.2337/dc22-S010
15. Garvey WT, Birkenfeld AL, Dicker D, et al. The Impact of Semaglutide 2.4 mg for Weight Management on Predicted 10-year Diabetes and Cardiovascular Risk. Diabetes Obes Metab. 2021;23(11):2201-2211. doi:10.1111/dom.14558
16. U.S. Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014 [Press release]. June 4, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
17. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 5 randomized clinical trial. JAMA. 2021;326(19):1834–1844. doi:10.1001/jama.2021.18556
18. O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649. doi:10.1016/S0140-6736(18)31773-2
19. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409. doi:10.1016/S0140-6736(17)30069-7
20. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788-803. doi:10.1161/CIRCRESAHA.114.301958
21. Seino Y, Terauchi Y, Osonoi T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378-388. doi:10.1111/dom.13063
22. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001
23. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892
24. Ludvik B, Hanefeld M, Irsigler K, et al. Effect of two years of treatment with exenatide on weight, HbA1c and the achievement of individualized glycaemic targets in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(6):515-521. doi:10.1111/dom.12066
25. Cai X, Han X, Luo Y, Ji L. Comparative efficacy and safety of antidiabetic drugs added to metformin monotherapy in patients with type 2 diabetes: A network meta-analysis. PLoS One. 2017;12(10):e0186549. Published 2017 Oct 4. doi:10.1371/journal.pone.0186549
